for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

argenx SE

ARGX.BR

Latest Trade

253.20EUR

Change

3.30(+1.32%)

Volume

38,743

Today's Range

252.70

 - 

273.60

52 Week Range

201.40

 - 

314.60

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
249.90
Open
258.30
Volume
38,743
3M AVG Volume
1.23
Today's High
273.60
Today's Low
252.70
52 Week High
314.60
52 Week Low
201.40
Shares Out (MIL)
51.40
Market Cap (MIL)
12,531.25
Forward P/E
-28.46
Dividend (Yield %)
--

Next Event

Q4 2021 argenx SE Earnings Release

Latest Developments

More

Argenx 9-Month Revenue Up At $471.3 Million

ArgenX To Highlight Potential FcRn Antagonist Efgartigimod At Upcoming Meetings

Argenx: Validation Of European Marketing Authorization Application For Efgartigimod

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About argenx SE

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Industry

Biotechnology & Drugs

Contact Info

Willemstraat 5

4811 AH

Netherlands

+31.76.3030488

https://www.argenx.com/

Executive Leadership

Peter K. M. Verhaeghe

Non-Executive Independent Chairman of the Board

Tim Van Hauwermeiren

Chief Executive Officer, Co-Founder, Executive Director

Werner Lanthaler

Non-Executive Independent Vice Chairman of the Board

Karl Gubitz

Chief Financial Officer

Keith Woods

Chief Operating Officer

Key Stats

1.86 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.1K

2020

0.1K

2021(E)

0.4K
EPS (USD)

2018

-2.282

2019

-4.731

2020

-14.310

2021(E)

-9.043
Price To Earnings (TTM)
--
Price To Sales (TTM)
29.67
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Argenx Announces Closing Of Global Offering

* GROSS PROCEEDS FROM GLOBAL OFFERING WERE APPROXIMATELY $862.5 MILLION Source text for Eikon: Further company coverage:

BRIEF-Argenx: Underwriters' Exercise Option To Purchase Additional ADSs

* ARGENX ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL ADSS

BRIEF-Argenx Announces Launch Of Proposed Global Offering

* ARGENX SE - COMMENCED A GLOBAL OFFERING OF $500 MILLION OF ORDINARY SHARES, WHICH MAY BE REPRESENTED BY AMERICAN DEPOSITORY SHARES Source text for Eikon: Further company coverage:

BRIEF-Argenx Announces Launch Of Proposed Global Offering

* HAS COMMENCED A GLOBAL OFFERING OF $500 MILLION OF ORDINARY SHARES, WHICH MAY BE REPRESENTED BY AMERICAN DEPOSITORY SHARES

BRIEF-Argenx Announces Positive Topline Results From Phase 3 ADAPT Trial Of Efgartigimod

* ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ADAPT TRIAL OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

BRIEF-Argenx Q1 Total Operating Income Down At 23.4 Million Euros

* ARGENX REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Argenx FY Operating Loss Widens To 178.6 Million Euros

* ARGENX REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES FOURTH QUARTER BUSINESS UPDATE

BRIEF-Argenx Announces Efgartigimod Phase 2 Trial Results

* ANNOUNCED ON TUESDAY RESULTS FROM THE COMPLETED PHASE 2 CLINICAL TRIAL OF ITS FCRN ANTAGONIST, EFGARTIGIMOD

BRIEF-Argenx Receives First Milestone Payment Under Janssen Collaboration

* ARGENX ANNOUNCED ON SATURDAY RECEIPT OF FIRST MILESTONE PAYMENT UNDER JANSSEN COLLABORATION AND PROVIDES DATA UPDATE FROM PHASE 1 DOSE ESCALATION TRIAL OF CUSATUZUMAB IN ACUTE MYELOID LEUKEMIA AT ASH ANNUAL MEETING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up